Blue Jet Healthcare Limited — Investor Meet, 08-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Blue Jet Healthcare reported Q2 FY'26 EBITDA of Rs. 60.1 Cr (36% margin) and PAT of Rs. 43.2 Cr. H1 FY'26 EBITDA was Rs. 182 Cr (+41% YoY) and PAT was Rs. 134.2 Cr (+36% YoY). Q2 revenue of Rs. 165 Cr was impacted by contrast media transit delays and phasing in Pharma Intermediates & API, though H1 revenue grew 40% YoY to Rs. 518 Cr. Gross margin variability was attributed to these transit issues. The company remains debt-free with Rs. 341 Cr liquidity.

Management highlighted strong order book visibility for contrast media, with a new iodinated intermediate expected to go commercial in Q4. A new sweetener shows encouraging development, targeting a global market of Rs. 100 Cr. Strategic expansions include a Rs. 1,000 Cr Vizag facility for contrast media, sweeteners, and peptide fragments by FY'28, and Mahad backward integration for Rs. 300 Cr commissioning by H2 FY'26. Management is confident about long-term growth, driven by innovation and customer partnerships.